NDC 70518-2273-04 - Cephalexin

This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.

Product NDC
70518-2273
Requested NDC
70518-2273-04
Package NDCs from labels
70518-2273-0, 70518-2273-1, 70518-2273-2, 70518-2273-3, 70518-2273-4, 70518-2273-5, 70518-2273-04
Manufacturer
REMEDYREPACK INC.
Effective date
2026-07-22
Current FDA listing
Not matched in FDA.report NDC product tables

DailyMed Labels#

Label, Manufacturer, Effective date table
LabelManufacturerEffective dateType
Cephalexin - REMEDYREPACK INC.REMEDYREPACK INC.2026-07-22HUMAN PRESCRIPTION DRUG LABEL
Cephalexin - Sportpharm LLCSportpharm LLC2026-02-03HUMAN PRESCRIPTION DRUG LABEL
Cephalexin - ASCLEMED USA INC.ASCLEMED USA INC.2025-06-18HUMAN PRESCRIPTION DRUG LABEL
Cephalexin - Asclemed USA, Inc. | ASCLEMED USA INC. DBA ENOVACHEMAsclemed USA, Inc. | ASCLEMED USA INC. DBA ENOVACHEM2024-06-21HUMAN PRESCRIPTION DRUG LABEL

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Related label table
NDCEffectiveRelated label
70518-2273-02023-03-09These highlights do not include all the information needed to use CEPHALEXIN CAPSULES safely and effectively. See full prescribing information for CEPHALEXIN CAPSULES. CEPHALEXIN capsules, for oral use Initial U.S. Approval: 1971
70518-2273-02023-03-09These highlights do not include all the information needed to use CEPHALEXIN CAPSULES safely and effectively. See full prescribing information for CEPHALEXIN CAPSULES. CEPHALEXIN capsules, for oral use Initial U.S. Approval: 1971
70518-2273-02023-03-09These highlights do not include all the information needed to use CEPHALEXIN CAPSULES safely and effectively. See full prescribing information for CEPHALEXIN CAPSULES. CEPHALEXIN capsules, for oral use Initial U.S. Approval: 1971
70518-2273-12023-03-09These highlights do not include all the information needed to use CEPHALEXIN CAPSULES safely and effectively. See full prescribing information for CEPHALEXIN CAPSULES. CEPHALEXIN capsules, for oral use Initial U.S. Approval: 1971
70518-2273-12023-03-09These highlights do not include all the information needed to use CEPHALEXIN CAPSULES safely and effectively. See full prescribing information for CEPHALEXIN CAPSULES. CEPHALEXIN capsules, for oral use Initial U.S. Approval: 1971
70518-2273-12023-03-09These highlights do not include all the information needed to use CEPHALEXIN CAPSULES safely and effectively. See full prescribing information for CEPHALEXIN CAPSULES. CEPHALEXIN capsules, for oral use Initial U.S. Approval: 1971
70518-2273-02023-01-30These highlights do not include all the information needed to use CEPHALEXIN CAPSULES safely and effectively. See full prescribing information for CEPHALEXIN CAPSULES. CEPHALEXIN capsules, for oral use Initial U.S. Approval: 1971
70518-2273-02023-01-30These highlights do not include all the information needed to use CEPHALEXIN CAPSULES safely and effectively. See full prescribing information for CEPHALEXIN CAPSULES. CEPHALEXIN capsules, for oral use Initial U.S. Approval: 1971
70518-2273-02023-01-30These highlights do not include all the information needed to use CEPHALEXIN CAPSULES safely and effectively. See full prescribing information for CEPHALEXIN CAPSULES. CEPHALEXIN capsules, for oral use Initial U.S. Approval: 1971
70518-2273-12023-01-30These highlights do not include all the information needed to use CEPHALEXIN CAPSULES safely and effectively. See full prescribing information for CEPHALEXIN CAPSULES. CEPHALEXIN capsules, for oral use Initial U.S. Approval: 1971
70518-2273-12023-01-30These highlights do not include all the information needed to use CEPHALEXIN CAPSULES safely and effectively. See full prescribing information for CEPHALEXIN CAPSULES. CEPHALEXIN capsules, for oral use Initial U.S. Approval: 1971
70518-2273-12023-01-30These highlights do not include all the information needed to use CEPHALEXIN CAPSULES safely and effectively. See full prescribing information for CEPHALEXIN CAPSULES. CEPHALEXIN capsules, for oral use Initial U.S. Approval: 1971

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
70518-2273-0Cephalexin30 in 1 BLISTER PACKCAPSULE3015
70518-2273-1Cephalexin14 in 1 BLISTER PACKCAPSULE1415
70518-2273-2Cephalexin30 in 1 BOTTLE, PLASTICCAPSULE3015
70518-2273-3Cephalexin28 in 1 BOTTLE, PLASTICCAPSULE2815
70518-2273-4Cephalexin40 in 1 BOTTLE, PLASTICCAPSULE4015
70518-2273-5Cephalexin28 in 1 BOTTLE, PLASTICCAPSULE2815

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
70518-2273CEPHALEXIN CAPSULE [REMEDYREPACK INC.]12Current NDC, Legacy NDC, 6 package rows20250311_a6b5edf2-1ef8-46b7-977a-8c303900f3f0.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
70518-2273-0EA - Each70518-22732f3daba0-ee0f-4d6b-9f94-b80054b19e3c12026-01-08

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 3 of 146 · 2,905 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
HERA SILKYSTAY FOUNDATION 17N1TITANIUM DIOXIDEAmorepacific Corporation5eb363fe-c2b2-9381-e063-6294a90ad0382026-10-25WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 17W1TITANIUM DIOXIDEAmorepacific Corporation5eb39387-7f6b-ce78-e063-6394a90a15ae2026-10-25WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 21C2TITANIUM DIOXIDEAmorepacific Corporation5eb3c3ad-8a77-0655-e063-6394a90ae9e02026-10-25WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 21N1TITANIUM DIOXIDEAmorepacific Corporation5eb3ddb5-4e2b-17d4-e063-6394a90aaa552026-10-25WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 22N1TITANIUM DIOXIDEAmorepacific Corporation5eb415b3-b1ba-42b8-e063-6394a90a90d72026-10-25WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 21W1TITANIUM DIOXIDEAmorepacific Corporation5eb42062-f298-5186-e063-6294a90ab0432026-10-25WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 23C2TITANIUM DIOXIDEAmorepacific Corporation5eb44e1b-b24b-6c83-e063-6394a90a4b522026-10-25WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 23W1TITANIUM DIOXIDEAmorepacific Corporation5eb468db-3c38-922d-e063-6294a90adef82026-10-25WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 24N1TITANIUM DIOXIDEAmorepacific Corporation5eb4b8ca-eced-b7ff-e063-6394a90aaefe2026-10-25WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 24O1TITANIUM DIOXIDEAmorepacific Corporation5eb4f87a-b4dc-1aa5-e063-6294a90a2ec42026-10-25WarningsExact identifier
unii: 15FIX9V2JP
HERA SILKYSTAY FOUNDATION 25W1TITANIUM DIOXIDEAmorepacific Corporation5eb50784-444e-3bf3-e063-6294a90aa6182026-10-25WarningsExact identifier
unii: 15FIX9V2JP
CephalexinCEPHALEXINREMEDYREPACK INC.c0ca008e-0e28-412e-a58f-70f63817713b2026-10-23Warnings, Adverse reactionsExact identifier
rxcui: 309112
unii: OBN7UDS42Y
KARYNG Complete SPF Sunscreen Medium/DarkSUNSCREENKaryng LLC335eee1e-ef1c-41da-e063-6294a90ac2732026-10-20WarningsExact identifier
unii: 15FIX9V2JP
KARYNG Complete SPF Sunscreen Light/MediumSUNSCREENKaryng LLC33596253-413d-fba3-e063-6394a90a39e42026-10-19WarningsExact identifier
unii: 15FIX9V2JP
CephalexinCEPHALEXINA-S Medication Solutions7cbdfa7f-2ea0-48e1-b506-59f58e5685a62026-10-19Warnings, Adverse reactionsExact identifier
application number: ANDA090836
rxcui: 309114
rxcui: 309112
unii: OBN7UDS42Y
CephalexinCEPHALEXINA-S Medication Solutions73920373-b45d-45d6-b183-d962467dde362026-10-19Warnings, Adverse reactionsExact identifier
application number: ANDA090836
rxcui: 309114
rxcui: 309112
unii: OBN7UDS42Y
CephalexinCEPHALEXINAscend Laboratories, LLC36882c6d-7b6f-41e3-8c54-e3b0073b8c072026-10-16Warnings, Adverse reactionsExact identifier
unii: OBN7UDS42Y
ALEX MD PHD Sheer Mineral SunscreenZINC OXIDE, TITANIUM DIOXIDEPHYSICIAN LABORATORIES INC8f64c4fa-92ee-4af0-ab1b-6c3673f9a6222026-10-16WarningsExact identifier
unii: 15FIX9V2JP
ALEX MD PHD Tinted Mineral SunscreenZINC OXIDE, TITANIUM DIOXIDEPHYSICIAN LABORATORIES INC93873c34-5c72-43c8-b6c2-c65b596191d72026-10-16WarningsExact identifier
unii: 15FIX9V2JP
CephalexinCEPHALEXINNorthwind Health Company, LLC4ecf9314-76e2-c270-e063-6294a90ad8db2026-10-16Warnings, Adverse reactionsExact identifier
application number: ANDA090836
unii: OBN7UDS42Y

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.